Company InMed Pharmaceuticals Inc Deutsche Boerse AG
Equities
CA13764X1069
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
|
05-14 | Earnings Flash (INM) INMED PHARMACEUTICALS Posts Q3 Revenue $1.2M | MT |
05-14 | InMed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
BayMedica
100.0
%
| 1 | 100.0 % | 4 | 100.0 % | +279.61% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Canada
100.0
%
| 1 | 100.0 % | 4 | 100.0 % | +279.61% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Eric Adams
CEO | Chief Executive Officer | 61 | 15/06/16 |
Chief Operating Officer | - | 04/11/18 | |
Colin Clancy
IRC | Investor Relations Contact | - | - |
Gerard Griffin
SAM | Sales & Marketing | - | 31/01/22 |
Eric Hsu
PRN | Corporate Officer/Principal | - | 12/03/18 |
General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Janet Grove
BRD | Director/Board Member | 57 | 10/02/22 |
Eric Adams
CEO | Chief Executive Officer | 61 | 15/06/16 |
Andrew Hull
CHM | Chairman | 61 | 11/09/16 |
Bryan Baldasare
BRD | Director/Board Member | 58 | 11/05/22 |
Nicole Lemerond
BRD | Director/Board Member | 48 | 07/08/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 14,137,034 | 14,054,505 ( 99.42 %) | 0 | 99.42 % |
Company contact information
InMed Pharmaceuticals, Inc.
815 West Hastings Street Suite 310
V6C 1B4, Vancouver
+604 669 7207
http://www.inmedpharma.com![address InMed Pharmaceuticals Inc](https://cdn.zonebourse.com/static/address/16538034.png)
Sector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
+20.03% | 126B | |
+23.61% | 118B | |
+23.26% | 27.87B | |
-18.07% | 20.95B | |
-15.13% | 16.92B | |
-14.81% | 16.18B | |
+9.78% | 14.84B | |
-46.10% | 14.79B | |
+52.34% | 14.08B |
- Stock Market
- Equities
- INM Stock
- Stock
- Company InMed Pharmaceuticals Inc